$5.21
-0.52 (-9.08%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where XAIR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional
Held by 1 tracked-famous manager (Balyasny Asset Management L.P.) · FINRA short interest 1.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic TumorsNCT05351502Incidence of AEs, SAEs and DLTs (safety) parameters.Non-randomized · Open-label · Treatment | Phase 1 | Unknown status | Drug: Nitric Oxide 25,000 ppm, Nitric Oxide 50,000 ppm, Nitric Oxide 100,000 ppm, Nitric Oxide selected dose | Cancer | 38 | 2025-05-30 | 2024-08-16 |
| Inhaled NO for the Treatment of Viral Pneumonia in AdultsNCT04606407incidence of Serious Adverse EventsRandomized · Open-label · Treatment | Not applicable | Completed | Device: LungFit™ | Viral Pneumonia, Nitric Oxide, Respiratory Disease, Pneumonia, Viral, Inhaled Nitric Oxide, Covid19, SARS-CoV Infection | 40 | 2022-08-07actual | 2022-12-16 |
| A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF PatientsNCT04685720Treatment-Emergent SAEsOpen-label · Treatment | Not applicable | Completed | Device: LungFit | Non-Tuberculous Mycobacterial Pneumonia, Cystic Fibrosis, Mycobacterial Pneumonia, Mycobacterium Abscessus Infection, Mycobacterium Avium Complex | 15 | 2022-07-28actual | 2022-12-16 |
| Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)NCT04456088Time to deteriorationRandomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Terminated (halted prematurely) | Combination product: 150 ppm Nitric Oxide delivered through LungFit Delivery System, 80 ppm Nitric Oxide delivered through LungFit Delivery System | COVID-19, SARS-CoV 2, Respiratory Disease, Pneumonia, Viral, Corona Virus Infection | 0 | 2020-11-15 | 2021-01-22 |
| Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)NCT04397692Time to deteriorationRandomized · Open-label · Device feasibility | Not applicable | Terminatedsponsor's stated reason: Slow recruitment | Device: Nitric Oxide delivered via LungFit™ system | Corona Virus Infection, COVID-19, SARS-CoV 2, Nitric Oxide, Respiratory Disease, Pneumonia, Viral, Inhaled Nitric Oxide | 4 | 2020-09-30actual | 2022-12-16 |
| Evaluation of Two Doses of Nitric Oxide (NO) Given Intermittently Via Inhalation to Subjects With BronchiolitisNCT04060979Time to "fit for discharge"Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Nitric Oxide · Other: Standard Supportive treatment | Bronchiolitis Acute | 95 | 2020-03-02actual | 2020-05-12 |
| Inhaled Nitric Oxide for Patients With MABSCNCT03208764Safety measured by NO-related Serious Adverse EventsOpen-label · Treatment | Phase 2 | Completed | Drug: Nitric Oxide | Mycobacterium Abscessus Infection | 9 | 2018-05-01actual | 2019-07-09 |
| Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With BronchiolitisNCT03053388Hospital Length of Stay (LOS)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Nitric Oxide · Other: Supportive treatment | Bronchiolitis | 69 | 2018-04-28actual | 2019-07-09 |
| Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation to Subjects With BronchiolitisNCT01768884Met-Hemoglobin percentage (MetHb) associated with inhaled NORandomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: Nitric Oxide, Placebo | Bronchiolitis | 43 | Jan 2016actual | 2016-05-04 |
| Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic FibrosisNCT01958944Met-Hemoglobin percentage (MetHb)associated with inhaled NOOpen-label · Treatment | Phase 1/2 | Completed | Drug: Nitric oxide | Cystic Fibrosis | 9 | Nov 2015actual | 2016-06-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19